Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Placebo-Controlled Trial of MK-8931 in Mild to Moderate Alzheimer's Disease
2011-003151-20Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of verubecestat in Alzheimer's disease (AD), sponsored by Merck & Co.. Started Oct 2012; status: terminated.
02
Drugs
verubecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2011-003151-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003151-20.